January 20, 2006 -- AVI BioPharma said three independent preclinical studies showed the efficacy of a new flu therapy, including the ability to treat avian flu; Inspire Pharma discontinued development of its drug for macular edema; Dendreon will cut back its research efforts and concentrate on its prostate cancer vaccine, Provenge; SuperGen withdrew its application for European approval of a treatment for pancreatic cancer; PDI, an independent biopharma sales and marketing company, will help Align Pharma sell its 3 recently acquired cancer drugs; and Dor BioPharma reported a positive survival benefit of orBec, its treatment for gastrointestinal Graft-versus-Host disease (iGVHD). Following the broad market, the Centient Bitoech 200™ moved 76 points lower to 3978.88, a loss of 1.88%. More details...
